Branded Legacy Inc (BLEG) fair value: what the stock is really worth
As of Oct 30, 2026: fair value (intrinsic value) of Branded Legacy Inc stock $0.01, price $0.00, upside +200.0%, quality 39 out of 100. Rating: strongly undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Oct 29, 2026.
How to read this chart
60‑month range $0.0022 – $35,530 · fair‑value band $0.0055 – $0.0071 · the $0.0022 price screens below the $0.0066 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Oct 29, 2026.
Follow Branded Legacy in your weekly email
Every Wednesday you see whether Branded Legacy is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Branded Legacy Inc engages in the commercial development of hemp and cannabinoid-infused beverages in Central Florida. It provides CBD topicals and tinctures, and hemp coffees and teas. The company was formerly known as Elev8 Brands, Inc. and changed its name to Branded Legacy Inc in May 2020.
Show moreShow less
Branded Legacy Inc. was incorporated in 1981 and is headquartered in Melbourne, Florida.
Stock analysis
Branded Legacy Inc (BLEG) currently trades at $0.0022, while our model-based Fair Value estimate is $0.0066, implying the stock looks roughly 66.7% undervalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of $0.0100 per share, and 6 of the 6 models we run sit above the $0.0022 price.
Bear case: the DCF Models group reads lowest at $0.0100, and 0 of the 6 models stay below the price. Data coverage for this calculation is low.
Scenario range: $0.0055 (bear) to $0.0071 (bull), the price of $0.0022 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Branded Legacy Inc reported revenue of $492K in FY2025 versus $64.3K in FY2021, a compound +66.3%/yr. Reported net income was −$382K in FY2025.
Key figures
Market cap $431K · P/S ratio 4.91 · EPS (TTM) $−0.5500 · Net margin −77.8% · Return on assets (EBIT) 313% · Operating margin −357% · Revenue growth (YoY) −46.9% · Free cash flow $69.5K.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 5 out of 100 (low confidence).
What moves the price
The share trades about 100% below its 52-week high and at its 52-week low.
For context, the median of 10 Healthcare peers we cover trades at −28% fair-value upside, at 200%, BLEG screens cheaper than that median.
Fair Value models
Bear$0.0055Fair Value $0.0066Bull$0.0071
Price $0.0022 · Upside +200.0%
Capped: our models arrive at a very high value here. We deliberately show a more cautious Fair Value.
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.59/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+915.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+31.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+37.3%
Start year 2020 (pandemic). Over 10 years: +40.1% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+40.1%
’15
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−296.6% (2020) → −71.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 552 stocks
Beats the industry median on 1/5 measures
Overall it trails its industry peers.
Valuation
Quality Score39 · Bottom 25%
Fair Value upside+200.0% · Top 25%
Profitability
Return on equity (12 months)Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets−97.0% · Bottom 25%
Net margin (12 months)−77.8% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)−46.9% · Bottom 25%
Balance sheet
Debt / equityNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/BNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)100· sector 17
FUTURE (revenue growth)0· sector 25
PAST (return on equity)0· sector 29
HEALTH (low debt)0· sector 96
DIVIDEND (yield)0· sector 33
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Branded Legacy Inc (BLEG) overvalued or undervalued?
As of Oct 29, 2026, our model estimates a fair value of $0.0066 versus a price of $0.0022, about +200% upside (undervalued).
What is the fair value of BLEG?
Our model-based fair value for Branded Legacy Inc is $0.0066 (as of Oct 29, 2026), built from audited fundamentals. The current price: $0.0022.
What is the quality score of BLEG?
Branded Legacy Inc has a Quality Score of 39/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Branded Legacy Inc (BLEG)?
Our model-based price target is the fair value of $0.0066 (as of Oct 29, 2026) from 6 valuation models. Cautious scenario $0.0055, optimistic scenario $0.0071. It is a calculation from audited fundamentals, not an analyst target.
What is the Branded Legacy Inc stock forecast for 2026?
Our models put fair value at $0.0066, about +200% upside versus a price of $0.0022 (undervalued). Cautious scenario $0.0055, optimistic scenario $0.0071. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Branded Legacy Inc (BLEG)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Branded Legacy Inc it is $0.0066 per share (as of Oct 29, 2026), against a price of $0.0022. It is the blended result of 6 valuation models (cash flow, earnings, asset, dividend).
Is Branded Legacy Inc stock overvalued or undervalued in 2026?
As of Oct 29, 2026, BLEG trades below its calculated fair value: price $0.0022, fair value $0.0066, a gap of about +200% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BLEG?
No. The price is what the market pays today ($0.0022); the fair value is what the company's own numbers justify ($0.0066). For Branded Legacy Inc the two are $0.0044 per share apart. That gap is exactly why we show both numbers side by side.
How much is Branded Legacy Inc worth?
The market values Branded Legacy Inc at about $431K (market capitalisation, as of Oct 29, 2026). Per share that is $0.0022; our models calculate a fair value of $0.0066 per share.
What do the bullish and bearish scenarios say about BLEG?
Our models span a range for Branded Legacy Inc: cautious scenario $0.0055, base $0.0066, optimistic $0.0071 per share (as of Oct 29, 2026, price $0.0022). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Branded Legacy Inc (BLEG)?
Balance-sheet figures for Branded Legacy Inc (as of Oct 29, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 39/100, which measures business quality independently of the share price.
How far is BLEG from its 52-week high?
Branded Legacy Inc trades at $0.0022, about 100% below its 52-week high of $1.00 and at the low of $0.0022 (as of Oct 30, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0066 is for.
Which stocks are comparable to Branded Legacy Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Jiangsu Hengrui Pharmaceuticals Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Branded Legacy Inc stock attractive at the current price?
The data as of Oct 29, 2026: price $0.0022, calculated fair value $0.0066 (+200%), Quality Score 39/100, from 6 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BLEG calculated?
We run Branded Legacy Inc through 6 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0066, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. Branded Legacy Inc currently trades 67 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Branded Legacy Inc (BLEG)?
The closing price on Oct 30, 2026 was $0.0022. Our model-based fair value is $0.0066, about +200% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Branded Legacy Inc right now?
The large discount to fair value meets weak quality (39/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case ($0.0055). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Branded Legacy Inc
How large is the market capitalisation of Branded Legacy Inc (BLEG)?
The market capitalisation of Branded Legacy Inc is $431K. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Branded Legacy Inc (BLEG)?
The price-to-sales ratio of Branded Legacy Inc is 4.91 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Branded Legacy Inc (BLEG)?
Earnings per share at Branded Legacy Inc are $−0.5500. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Branded Legacy Inc (BLEG)?
The net margin of Branded Legacy Inc is −77.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the EBIT return on assets of Branded Legacy Inc (BLEG)?
On an EBIT basis the return on assets of Branded Legacy Inc is 313% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Branded Legacy Inc (BLEG)?
The operating margin of Branded Legacy Inc is −357% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Branded Legacy Inc (BLEG)?
Revenue at Branded Legacy Inc is growing −46.9% versus a year earlier (3y avg +31.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Branded Legacy Inc (BLEG) generate?
The free cash flow of Branded Legacy Inc is $69.5K (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Branded Legacy Inc (BLEG) carry?
The net debt of Branded Legacy Inc is $1.7M (fiscal year 2025, ≈ 24.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Branded Legacy Inc in the live analysis
One click puts Branded Legacy Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Oct 29, 2026